سعر فاتستاتين 20 مجم 10 أقراص 2022

Atorvastatin 20 mg oral film-coated tablets (Sea Pharm / EGPI), pack of 10.

• To reduce the risk of MI, stroke, revascularization procedures and angina in adults with multiple CHD risk factors but without clinically evident CHD, and of MI and stroke in adults with type 2 diabetes with multiple CHD risk factors.DailyMed (U.S. NLM)
• To reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization, hospitalization for congestive heart failure and angina in adults with clinically evident CHD.DailyMed (U.S. NLM)
• Adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia and in adults and children 10 years and older with heterozygous familial hypercholesterolemia; with other LDL-C-lowering therapies (or alone) in homozygous familial hypercholesterolemia (10 years and older).DailyMed (U.S. NLM)

• Most common (2% or more and above placebo): nasopharyngitis, arthralgia, diarrhoea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain; myalgia, diarrhoea, nausea and liver enzyme increases were the commonest reasons for discontinuation.International label, same formulation · DailyMed (U.S. NLM)

• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. NLM)
• Hypersensitivity to atorvastatin or any excipient (anaphylaxis, angioneurotic oedema, erythema multiforme, SJS and TEN reported).International label, same formulation · DailyMed (U.S. NLM)

• Myopathy and rhabdomyolysis (with acute kidney injury); risk increased by age 65 or more, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher doses. Discontinue if markedly elevated CK or myopathy is diagnosed or suspected.International label, same formulation · DailyMed (U.S. NLM)
• Immune-mediated necrotizing myopathy has been reported rarely; discontinue if suspected.International label, same formulation · DailyMed (U.S. NLM)
• Hepatic dysfunction: transaminase increases; consider liver enzyme tests before starting and when clinically indicated; discontinue promptly if serious hepatic injury occurs.International label, same formulation · DailyMed (U.S. NLM)

• Cyclosporine, gemfibrozil, tipranavir plus ritonavir, glecaprevir plus pibrentasvirConcomitant use is not recommended (increased atorvastatin exposure and myopathy/rhabdomyolysis risk).DailyMed (U.S. NLM)
• Clarithromycin, itraconazole, saquinavir/ritonavir, darunavir/ritonavir, fosamprenavir, elbasvir/grazoprevir, letermovirDo not exceed atorvastatin 20 mg once daily.DailyMed (U.S. NLM)
• NelfinavirDo not exceed atorvastatin 40 mg once daily.DailyMed (U.S. NLM)

• Discontinue when pregnancy is recognised (or consider ongoing therapeutic needs); may cause fetal harm based on mechanism of action. Observational data over decades of statin use have not identified a drug-associated risk of major congenital malformations.International label, same formulation · DailyMed (U.S. NLM)
• Breastfeeding is not recommended during treatment (potential for serious adverse reactions in the infant; atorvastatin is present in rat milk).International label, same formulation · DailyMed (U.S. NLM)

• Atorvastatin: Selective, competitive inhibitor of HMG-CoA reductase, lowering hepatic cholesterol synthesis and increasing hepatic LDL receptors (US Lipitor label).